Evidence map›Paper›PMID 38246191›Full record

ArticleThe Lancet. Infectious diseases2024

Effectiveness of one dose of killed oral cholera vaccine in an endemic community in the Democratic Republic of the Congo: a matched case-control study.

Espoir Bwenge Malembaka, Patrick Musole Bugeme, Chloe Hutchins, Hanmeng Xu, Juan Dent Hulse, Maya N Demby, Karin Gallandat, Jaime Mufitini Saidi, Baron Bashige Rumedeka, Moïse Itongwa and 17 more

Erratum issuedOpen access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Lancet. Infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
11.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Vaccines · 2025
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Effectiveness of the Euvichol® oral cholera vaccine at 2 years: A case-control and bias-indicator study in Haiti.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2024
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

27 authors at 9 institutions in 4 countries.

Espoir Bwenge MalembakaDepartment of Epidemiology, Johns Hopkins University, Baltimore, MD, USA; Centre for Tropical Diseases and Global Health (CTDGH), Université Catholique de Bukavu, Bukavu, Democratic Republic of the Congo.
Patrick Musole BugemeDepartment of Epidemiology, Johns Hopkins University, Baltimore, MD, USA; Centre for Tropical Diseases and Global Health (CTDGH), Université Catholique de Bukavu, Bukavu, Democratic Republic of the Congo.
Chloe HutchinsDepartment of Disease Control, London School of Hygiene & Tropical Medicine, London, UK.
Hanmeng XuDepartment of Epidemiology, Johns Hopkins University, Baltimore, MD, USA.
Juan Dent HulseDepartment of Epidemiology, Johns Hopkins University, Baltimore, MD, USA.
Maya N DembyDepartment of Epidemiology, Johns Hopkins University, Baltimore, MD, USA.
Karin GallandatDepartment of Disease Control, London School of Hygiene & Tropical Medicine, London, UK.
Jaime Mufitini SaidiMinistère de la Santé Publique, Hygiène et Prévention, Zone de Santé d'Uvira, Uvira, Democratic Republic of the Congo.
Baron Bashige RumedekaDepartment of Epidemiology, Johns Hopkins University, Baltimore, MD, USA.
Moïse ItongwaOxfam DRC, Uvira, Democratic Republic of the Congo.
Esperance Tshiwedi-TsilabiaRodolphe Merieux INRB-Goma Laboratory, Goma, North Kivu, Democratic Republic of the Congo.
Faida KitogaRodolphe Merieux INRB-Goma Laboratory, Goma, North Kivu, Democratic Republic of the Congo.
Tavia Bodisa-MatamuRodolphe Merieux INRB-Goma Laboratory, Goma, North Kivu, Democratic Republic of the Congo.
Hugo Kavunga-MemboRodolphe Merieux INRB-Goma Laboratory, Goma, North Kivu, Democratic Republic of the Congo; Institut National de Recherche Biomédicale, INRB, Kinshasa, Democratic Republic of the Congo.
Justin BengehyaMinistère de la Santé Publique, Hygiène et Prévention, Division Provinciale de la Sante' Publique du Sud-Kivu, Bukavu, Democratic Republic of the Congo.
Jean-Claude KulondwaMinistère de la Santé Publique, Hygiène et Prévention, Division Provinciale de la Sante' Publique du Sud-Kivu, Bukavu, Democratic Republic of the Congo.
Amanda K DebesDepartment of International Health, Johns Hopkins University, Baltimore, MD, USA.
Nagède TatyPNECHOL-MD, Community IMCI, Ministry of Health, Kinshasa, Democratic Republic of the Congo.
Elizabeth C LeeDepartment of Epidemiology, Johns Hopkins University, Baltimore, MD, USA.
Octavie LunguyaInstitut National de Recherche Biomédicale, INRB, Kinshasa, Democratic Republic of the Congo; Service of Microbiology, Department of Medical Biology, University of Kinshasa, Kinshasa, Democratic Republic of the Congo.
Justin LesslerDepartment of Epidemiology, Johns Hopkins University, Baltimore, MD, USA; University of North Carolina Population Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Daniel T LeungDivision of Infectious Diseases and Division of Microbiology and Immunology, University of Utah School of Medicine, Salt Lake City, Utah, USA.
Oliver CummingDepartment of Disease Control, London School of Hygiene & Tropical Medicine, London, UK.
Placide Welo OkitayembaPNECHOL-MD, Community IMCI, Ministry of Health, Kinshasa, Democratic Republic of the Congo.
Daniel Mukadi-BamulekaRodolphe Merieux INRB-Goma Laboratory, Goma, North Kivu, Democratic Republic of the Congo; Institut National de Recherche Biomédicale, INRB, Kinshasa, Democratic Republic of the Congo; Service of Microbiology, Department of Medical Biology, University of Kinshasa, Kinshasa, Democratic Republic of the Congo.
Jackie KneeDepartment of Disease Control, London School of Hygiene & Tropical Medicine, London, UK.
Andrew S AzmanDepartment of Epidemiology, Johns Hopkins University, Baltimore, MD, USA; Geneva Centre for Emerging Viral Diseases and Division of Tropical and Humanitarian Medicine, Geneva University Hospitals, Geneva, Switzerland. Electronic address: azman@jhu.edu.
Johns Hopkins University · USMinistry of Public Health · CDLondon School of Hygiene & Tropical Medicine · GBUniversity of Kinshasa · CDNational Institute of Biomedical Research · CDUniversité Catholique de Bukavu · CDUniversity Hospital of Geneva · CHUniversity of North Carolina at Chapel Hill · USUniversity of Utah · US

Funding

Wellcome Trust
6 · The paper itself

Abstract

backgroundA global shortage of cholera vaccines has increased the use of single-dose regimens, rather than the standard two-dose regimen. There is sparse evidence on single-dose protection, particularly in children. In 2020, a mass vaccination campaign was conducted in Uvira, an endemic urban setting in eastern Democratic Republic of the Congo, resulting in largely single-dose coverage. We examined the effectiveness of a single-dose of the oral cholera vaccine Euvichol-Plus in this high-burden setting.

methodsIn this matched case-control study, we recruited individuals with medically attended confirmed cholera in the two cholera treatment facilities in the city of Uvira. The control group consisted of age-matched, sex-matched, and neighbourhood-matched community individuals. We recruited across two distinct periods: Oct 14, 2021, to March 10, 2022 (12-17 months after vaccination), and Nov 21, 2022, to Oct 18, 2023 (24-36 months after vaccination). Study staff administered structured questionnaires to all participants to capture demographics, household conditions, potential confounding variables, and vaccination status. The odds of vaccination for the case and control groups were contrasted in conditional logistic regression models to estimate unadjusted and adjusted vaccine effectiveness.

findingsWe enrolled 658 individuals with confirmed cholera and 2274 matched individuals for the control group. 99 (15·1%) individuals in the case group were younger than 5 years at the time of vaccination. The adjusted single-dose vaccine effectiveness was 52·7% (95% CI 31·4 to 67·4) 12-17 months after vaccination and 44·7% (24·8 to 59·4) 24-36 months after vaccination. Although protection in the first 12-17 months after vaccination was similar for children aged 1-4 years and older individuals, the estimate of protection in children aged 1-4 years appeared to wane during the third year after vaccination (adjusted vaccine effectiveness 32·9%, 95% CI -30·7 to 65·5), with CIs spanning the null.

interpretationA single dose of Euvichol-Plus provided substantial protection against medically attended cholera for at least 36 months after vaccination in this cholera-endemic setting. Although the evidence provides support for similar levels of protection in young children and others in the short term, protection among children younger than 5 years might wane significantly during the third year after vaccination.

fundingWellcome Trust and Gavi, the Vaccine Alliance.

Indexed as

CholeraCholera VaccinesVaccines, InactivatedAdministration, OralAdolescentAdultCase-Control StudiesChildChild, PreschoolDemocratic Republic of the CongoEndemic DiseasesFemaleHumansInfantMaleMass VaccinationCholera VaccinesVaccines, Inactivated

Identifiers

PMID38246191
PMCPMC11043051
OpenAlexW4391066307

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.